Cochrane Review Finds Insufficient Evidence for Cannabis as Insomnia Treatment
A new review published by the Cochrane Library has found insufficient evidence to support the use of medical-grade cannabis for treating insomnia. The analysis, which examined nine clinical trials, highlights significant gaps in the current research and calls for better-quality studies.
Editor, Lazyfounder
30 SEC SUMMARY
- A Cochrane review found insufficient evidence to support medical-grade cannabis as an effective treatment for insomnia.
- The review analyzed nine studies with 537 participants, most focusing on primary insomnia.
- No clear benefit was observed for cannabis compared to placebos or amitriptyline in improving sleep outcomes.
- Adverse effects like dry mouth and dizziness were more common among cannabis users.
- Researchers call for larger, higher-quality studies to draw definitive conclusions.
TABLE OF CONTENTS
KEY HIGHLIGHTS
- A Cochrane review evaluated the effectiveness of medical-grade cannabis for treating insomnia, finding insufficient evidence to support its use.
- The analysis included nine studies with 537 participants aged 18 to 76, primarily focusing on primary insomnia.
- Cannabis showed no clear superiority over placebos or amitriptyline in metrics like sleep quality, total sleep time, or daytime functioning.
- Adverse events, including dry mouth and dizziness, were more frequent among cannabis users.
- Studies were limited by small sample sizes, short follow-up periods (up to 12 weeks), and a high risk of bias.
What the review found
A comprehensive review published by the Cochrane Library assessed the effectiveness of medical-grade cannabis for treating insomnia. According to Gizmodo, the review concluded that there is insufficient evidence to support its use. The analysis included nine randomized clinical trials involving 537 participants aged 18 to 76.
The studies primarily focused on primary insomnia—insomnia not linked to another health condition—and compared cannabis to placebos or the antidepressant amitriptyline. The review found no metric in which cannabis demonstrated clear superiority over control treatments for outcomes such as sleep quality, total sleep time, or daytime functioning.
Limitations in current research
The Cochrane review identified several limitations in the existing research. Many studies had small sample sizes, short follow-up periods (with the longest being 12 weeks), and a high risk of bias. Additionally, the studies used different types of cannabis, which complicates comparisons and conclusions.
Adverse events, such as dry mouth and dizziness, were reported more frequently among participants using cannabis. However, the review noted that the overall evidence on the safety of medical cannabis for insomnia remains limited.
Call for better-quality studies
The authors of the review, including neurologist Lucia Varela from the University of Manitoba, emphasized the need for larger and more rigorous studies to determine whether medical cannabis can effectively treat insomnia. They stressed the importance of well-defined products and standardized dosing to improve the reliability of future research.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
This Cochrane review underscores a critical gap in the evidence supporting medical cannabis as a treatment for insomnia. For founders and operators in the cannabis and sleep health spaces, the findings are a reminder that marketing claims must align with scientific rigor. While consumer interest in cannabis-based sleep aids is growing—particularly among younger adults—startups must resist the temptation to overstate benefits without robust clinical backing.
The review also signals an opportunity for innovation in research methodologies. Current studies are plagued by small sample sizes, inconsistent product definitions, and short follow-up periods. Companies that invest in well-designed, large-scale trials could not only fill this evidence gap but also gain a competitive edge in a market where trust and credibility are increasingly valuable. For investors, this review is a cautionary note: due diligence should prioritize startups committed to transparent, high-quality research over those making unverified claims.
Key takeaways
- Founders in the cannabis or sleep health industries should avoid overstating the benefits of cannabis for insomnia until stronger evidence emerges.
- Operators must prioritize rigorous clinical trials to address gaps in current research, focusing on standardized dosing and product definitions.
- The review highlights the importance of transparent communication about adverse effects to patients and consumers.
- Investors should approach insomnia-related cannabis ventures cautiously, favoring startups with a commitment to high-quality research.
- The lack of evidence presents an opportunity for startups to lead in well-designed studies that could shape future regulatory and medical guidelines.
FAQ
What is the Cochrane Library?
The Cochrane Library is a collection of databases that publishes systematic reviews of healthcare research. These reviews are widely respected and used to inform medical guidelines and policies.
Why does this review matter for startups in the cannabis industry?
This review matters because it highlights the lack of strong evidence supporting medical cannabis as a treatment for insomnia. Startups must ensure their claims are backed by rigorous research to avoid regulatory risks and build consumer trust.
What were the main limitations of the studies included in the review?
The main limitations included small sample sizes, short follow-up periods, high risk of bias, and inconsistent use of cannabis products across studies.
Related on Lazyfounder
Sources
- Gizmodo · 2026-10-13
Cannabis for Insomnia? The Verdict Is Shaky, Review Finds
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.
